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ABSTRACT
Bisphosphonatesarethefirst-linetreatment forpreventingfractures inosteoporosispatients.However, theiruse iscontraindicatedor tobeused
withcaution inchronickidneydisease(CKD)patients,primarilybecauseofa lackof informationabouttheirsafetyandeffectiveness.Weaimedto
investigate thesafetyoforalbisphosphonates inpatientswithmoderate tosevereCKD,usingprimary-careelectronic records fromtwocohorts,
CPRDGOLD (1997–2016) and SIDIAP (2007–2015) in theUK andCatalonia, respectively. Bothdatabaseswere linked to hospital records. SIDIAP
was also linked to end-stage renal disease registry data. PatientswithCKD stages 3b to 5, basedon twoormore estimatedglomerular filtration
rate measurements less than 45 mL/min/1.73 m2, aged 40 years or older were identified. New bisphosphonate users were propensity score–
matchedwithuptofivenon-users tominimizeconfoundingwithin thispopulation.OurprimaryoutcomewasCKDstageworsening (estimated
glomerularfiltrationrate [eGFR]declineor renal replacement therapy). Secondaryoutcomeswereacutekidney injury,gastrointestinalbleeding/
ulcers, and severe hypocalcemia. Hazard ratios (HRs) were estimated using Cox regression and Fine and Gray sub-HRs were calculated for
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competing risks. Wematched 2447 bisphosphonate users with 8931 non-users from CPRD and 1399 users with 6547 non-users from SIDIAP.
Bisphosphonate use was associated with greater risk of CKD progression in CPRD (sub-HR [95% CI]: 1.14 [1.04, 1.26]) and SIDIAP (sub-HR: 1.15
[1.04, 1.27]). No risk differences were found for acute kidney injury, gastrointestinal bleeding/ulcers, or hypocalcemia. Hence, we can conclude
amodest (15%) increased risk of CKDprogressionwas identified in associationwith bisphosphonate use. No other safety concernswere iden-
tified. Our findings should be considered before prescribing bisphosphonates to patients withmoderate to severe CKD. © 2020 The Authors.
Journal of BoneandMineral ResearchpublishedbyWileyPeriodicals LLConbehalf ofAmericanSociety forBoneandMineral Research (ASBMR)..
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Introduction
Moderate to severe (stages 3 to 5) chronic kidney disease(CKD) affects up to 2.8 million people in the United King-
dom (UK)(1) and 2.7 million people in Spain.(2) CKD is associated
with low bone mass.(3) Increased fracture risk is associated with
increasing CKD severity.(4–7)
Although bisphosphonates are first-line anti-osteoporosis ther-
apies for preventing fractures, their use is contraindicated or to be
used with caution in patients with an estimated glomerular filtra-
tion rate (eGFR) under 30 mL/min/1.73 m2. Clinical guidelines(8–10)
and drug regulators(11–13) impose similar restrictions.
A systematic review of the benefits and harms of anti-
osteoporosis medications, including bisphosphonates, suggested
that bisphosphonates did not increase the risk of renal adverse
events (373 patients from four trials), gastrointestinal events
(179 patients from two trials), or hypocalcemia (93 patients from
one trial).(14) The review acknowledged that most of the included
studies had possible reporting bias and that the results might not
apply to patients with stages 3b to 5 CKD because of scant evi-
dence in this population. Reporting bias was driven by selective
reporting of trial outcomes, unclear methods, and restricted study
designs (randomized trials with 6 to 36 months of follow-up). The
participants in the included trials were also far healthier than
bisphosphonate users in actual practice settings.
The most recent (2017) Kidney Disease Outcomes Quality Ini-
tiative guidelines(15) proposed that potential kidney progression,
the severity of any biochemical abnormalities, fracture risk, and
bone andmineral disorders related to CKD should be considered
when deciding whether to prescribe bisphosphonates. There is
an urgent need for data on the risks and benefits of bisphospho-
nates for patients with moderate to severe CKD.
Following a commissioned call from the UK National Institute
for Health Research, we analyzed routinely collected data from
Spain and the UK to establish the safety of bisphosphonates in
patients with stages 3b to 5 CKD. Our prespecified list of safety
events included CKDworsening (primary outcome), acute kidney




This study used a cohort design with data from two primary-care
electronic health record databases linked to hospital records.
We used 1997 to 2016 records from the UK’s Clinical Practice
Research Datalink (CPRD) GOLD linkedwith Hospital Episode Sta-
tistics (HES). CPRD-HES contains anonymized primary- and
secondary-care records from 401 English primary-care practices
(58% of CPRD-registered practices). In CPRD, practices suitable
for research purposes are considered “up to standard”. (16)
We also used 2007 to 2015 records from Catalonia’s Informa-
tion System for the Development of Research in Primary Care
(SIDIAP) linked with the National Hospital Discharge Database
and renal registry. SIDIAP contains information on 5.8 million
patients from 279 practices in the Catalonia region of Spain,
representing 80% of that population.(17)
Both data sets are representative of their respective popula-
tions.(18,19) The replication of analyses from CPRD in SIDIAP was
undertaken to check the generalizability of results identified in
the UK to other European countries. Differences between CPRD
and SIDIAP are mainly due to difference in the population, since
the data sets collect data in the samemanner. Scientific approval
was obtained for CPRD (protocol number 15_153R2) and SIDIAP
(protocol number 148). Data were extracted and analyzed by
independent statisticians using an agreed common data struc-
ture and shared programming codes.
Study population
Our target population was patients with two or more eGFR mea-
surements under 45 mL/min/1.73 m2, aged 40 years or older.
Patients had to be registered with a practice considered “up to
standard” by that database for at least 1 year before their first
low eGFR measurement. eGFR estimates were obtained directly
from biochemistry data and calculated using the CKD Epidemiol-
ogy Collaboration formula based on serum creatinine if auto-
mated laboratory reporting of eGFR was not available.(20)
Patients were excluded if they had used bisphosphonates in
the year before their index date (first bisphosphonate use), used
non-oral bisphosphonate anti-osteoporotic therapies at any time
before their index date, were missing index of multiple depriva-
tion information (social deprivation level in CPRD), or had no
follow-up eGFR measurement.
Study exposure: bisphosphonate use
Oral bisphosphonate prescriptions (CPRD) and dispensations
(SIDIAP) were identified using previously validated lists of prod-
codes in CPRD and anatomic therapeutic chemical classification
(ATC) codes in SIDIAP. All participants joined the study unexposed
to bisphosphonates on their second eGFR measurement under
45 mL/min/1.73 m2. Participants could contribute both exposed
and unexposed time, as illustrated in Supplemental Fig. S1. Partic-
ipants were followed until the end of enrollment in the database
(moving out, death, or 10 years), an incident record of the out-
come of interest, stopping treatment (6 months), or switching
treatment (bisphosphonate users only). A washout period of
6 months plus 30 days from the last prescription or dispensation
accounted for carry-over effects. Code lists are provided in
https://github.com/vystrauss/BisCK/tree/master.
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Outcomes
The primary outcome was CKD stage worsening, based on
follow-up annual eGFR measurements in primary-care records,
dialysis, a kidney transplant recorded in CPRD-HES with relevant
codes from the 10th revision of the International Statistical Clas-
sification of Diseases and Related Health Problems (ICD-10) or
fourth version of the OPCS Classification of Interventions and
Procedures (OPCS-4), or a record in the renal registry in SIDIAP.
CKD stage worsening included a move from stage 3b (eGFR
30 to 45 mL/min/1.73 m2) to stage 4 (eGFR 15 to 30 mL/
min/1.73 m2) or 5 (eGFR less than 15 mL/min/1.73 m2), or from
stage 4 to 5.
The secondary outcomes of interest were hospitalization for
acute kidney injury; hospitalization for, or a primary-care record
of, peptic ulcer or gastrointestinal bleeding; and hospitalization
for hypocalcemia, identified with ICD-10 codes.
Covariates
Covariates were identified in a consensus meeting between two
clinicians and one epidemiologist using a predefined list of
potential confounders identified in the literature. Forty-five cov-
ariates were selected, including patient demographics, clinical
diagnoses identified with Read codes (CPRD) or ICD-10
(SIDIAP), and previous drug use ascertained using prodcodes
(CPRD) or ATC codes (SIDIAP). Covariates are listed in the foot-
note of Supplemental Fig. S2.
Statistical analyses
A propensity score (PS) was estimated using the 45 covariates
with logistic regression. The PS represented the probability of
receiving oral bisphosphonates based on the covariates and
exact matching on years of follow-up. Missing data for body
mass index, smoking category, drinking category (CPRD), and
creatinine (SIDIAP) were imputed in 10 data sets using multiple
imputation by chained equations, assuming data were missing
at random. Exposed participants were PS-matched with up to
five unexposed participants on a caliper width of 0.2 standard
deviations of the logit of the PS, without replacement. The abso-
lute standardized mean difference (ASMD) was used to evaluate
balance, with values below 0.1 indicating good balance.
Incidence rates and their 95% confidence intervals (CIs) were
reported per 1000 person-years in the PS-matched and full
cohorts. Unadjusted and fully adjusted Cox proportional hazard
models were used to calculate hazard ratios (HRs) for each of
the outcomes. Fine and Gray sub-HRs were calculated for the
PS-matched cohorts to account for any difference in death rate
due to PS matching. The proportionality assumption of all
models was checked using Schoenfeld Residuals. The propor-
tionality assumption held for all models (data not shown). We
combined the results from CPRD and SIDIAP in fixed-effects
meta-analyses to produce an overall estimate.
Numbers needed to harm after 3 and 5 years were calculated
from Kaplan–Meier curves for the primary outcome. Supplemen-
tal Materials and Methods contains the sample size calculation.
Additional and sensitivity analyses
Two predefined interactions with bisphosphonate use were
tested, sex and history of fracture at any location except the
digits, with a cut-off of p < .1. Stratified Fine and Gray regressions
were reported if there was evidence of significant interactions.
Medication possession ratios (MPR) were calculated as the num-
ber of defined daily doses from the first prescription/dispensa-
tion until 30 days after the last record, divided by the number
of days within this time window. Fine and Gray models were
repeated for MPR quartiles (0 versus <0.83, 0.83–0.97,
0.97–1.05, and >1.05) to test the biological gradient of the
Bradford-Hill causality criteria.(21)
The effect of potential unmeasured confounding was mea-
sured using an array analysis(22) for any significant result in CPRD.
The percentage unexposed with the unmeasured confounder
was set at 30%, based on unpublished data. The array analysis
combined a range of values for the unmeasured variable’s
exposed prevalence (30% to 80%) and the association with the
study outcome (1.0 to 3.0) to adjust the main (estimated) treat-
ment effect size.
Data were analyzed in R version 3.3.2 (CPRD) and 3.5.1
(SIDIAP). Packages used included mice,(23) MatchIT,(24)
survival,(25) and survminer.(26)
The reporting guidelines of STROBE were followed when writ-
ing this article.
Results
We identified 217,405 patients with an eGFR ≤45 mL/
min/1.73 m2 in CPRD, of whom 53,986 patients contributed
unexposed time and 2613 bisphosphonate exposure time. We
identified 40,800 unexposed and 1408 exposed patients in
SIDIAP. Fig. 1 shows all exclusions. The most common reasons
for exclusion were not having two eGFR measurements and
not having any follow-up eGFR data available.
Across 10 imputed data sets, on average 2447 bisphospho-
nate users were matched with 8931 non-users in CPRD and
1399 users were matched with 6547 non-users in SIDIAP.
Table 1 reports characteristics after imputation and before and
after PS matching.
Participants were well-matched, including on key covariates
such as age, body mass index (BMI), and baseline eGFR, with
ASMDs of less than 0.1 for all covariates in the PS in both data
sets (Supplemental Materials andMethods), although there were
differences in rates (Table 1). In CPRD, the average age was
80 years with approximately 27% of patients male, whereas in
SIDIAP, the average age was 78 years with approximately 23%
of patients male.
In the PS-matched cohorts, participants were followed up for a
total of 7287 exposed and 26,731 unexposed person-years in
CPRD (median of 3.0 years for both users and non-users) and
3946 exposed and 20,152 unexposed person-years in SIDIAP
(median of 4.4 years for users and 4.8 years for non-users),
before censoring at an outcome of interest.
The risk of death differed between users and non-users in only
the PS-matched cohort from CPRD (HR [95% CI]: 0.67 [0.62, 0.73]).
CKD stage worsening
In CPRD, 2572 events occurred, including 229 dialysis or trans-
plant events. The incidence rate of CKD stage worsening was
89.1 (95% CI: 82.1, 96.7) per 1000 person-years in bisphospho-
nate users and 85.6 (82.0, 89.5) in non-users (Table 2). Fig. 2
shows the cumulative incidence of stage worsening and death.
The number needed to harmwas 40.8 after 3 years and 20.7 after
5 years.
Similar results were found in SIDIAP. There were 2482 events,
with incidence rates of 118.4 per 1000 person-years in users and
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100.0 in non-users. The number needed to harm was 29.4 after
3 years and 28.6 after 5 years.
Combining results from CPRD and SIDIAP gave a PS-matched
cohort sub-HR (95% CI) of 1.14 (1.07, 1.23) and a whole cohort HR
of 1.18 (1.11, 1.26) (Table 2). Supplemental Table S1 gives the full
results of the multiple regression model for CPRD.
In CPRD, significant interactions were identifiedwith history of
fracture (p = .03) and sex (p = .04). Those with a history of fracture
were more likely to experience stage worsening (sub-HR [95%
CI]: 1.36 [1.08, 1.71]) than those without a history of fracture
(1.10 [0.99, 1.22]), although the CIs overlapped. Women were
more likely to experience stage change (1.24 [1.11, 1.38]) than
men (1.00 [0.83, 1.21]).
Those in the highest MPR quartile ratio category were at high-
est risk of CKD stage worsening and those with the lowest ratio
were at least risk, although the CIs overlapped (Supplemental
Fig. S3).
The array analysis (Fig. 3A, B) showed that unmeasured con-
founding was unlikely to negate the identified risk of sub-HR
1.14 (1.04, 1.26). For the risk identified to be negated, more than
50% of the bisphosphonate users needed to have the con-
founder, with an sub-HR of 3.0 between the confounder and
CKD stage worsening. The presented results would bemore than
25% biased. The results would also be negated if more than 80%
of the participants had the confounder, with an association
(sub-HR) of 1.75 (results 20% biased).
Acute kidney injury
The PS-matched CPRD and SIDIAP cohorts contained 482 and
597 acute kidney injury events, respectively. There was no signif-
icant difference in the risk of developing an acute kidney injury
between bisphosphonate users and non-users, with a combined
sub-HR (95% CI) of 0.92 (0.78, 1.08) (Table 2).
No significant interactions were identified in sensitivity ana-
lyses. Less than 15% of the participants experienced an acute
kidney injury within 10 years (Supplemental Fig. S4). Participants
exposed to bisphosphonates with an MPR between 97% and
105.2% had a lower risk of acute kidney injury than if matched
to unexposed patients (sub-HR [95% CI]: 0.55 [0.32, 0.94]). How-
ever, no dose-response effect was found.
Gastrointestinal events
The rates of gastrointestinal events were 5.5 (4.0, 7.5) per 1000
patient-years for users and 6.4 (5.5, 7.4) for non-users in the CPRD
PS-matched cohort and 1.9 (0.9, 3.5) for users and 1.9 (1.4, 2.5) for
non-users in the SIDIAP PS-matched cohort. No difference was
found between users and non-users in any of the cohorts
(Table 2).
No interactions were identified in sensitivity analyses. More
than 95% of participants did not experience a gastrointestinal
event within 10 years (Supplemental Fig. S5).
Fig 1. Flow diagrams for patient exclusions in CPRD (left) and SIDIAP (right) identifying when and why patients were excluded from each data set.
*Patients contribute both unexposed and exposed time. See Supplemental Fig. S1 for full explanation. eGFR = estimated glomerular filtration rate in
mL/min/1.73 m2; IMD = index of multiple deprivation.
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Hypocalcemia
Hospitalization for hypocalcemia was rare. There was no differ-
ence in risk in CPRD, with an sub-HR of 0.34 (0.08, 1.43) for the
PS-matched cohort. The sub-HR was not calculated for the
SIDIAP cohort due to the few events. More than 99% of partici-
pants did not experience hypocalcemia within 10 years (data
not shown) in both cohorts.
Discussion
Statement of principal findings
We used routinely collected data from primary-care practices
and hospitals in the UK and Spain and linked renal registry infor-
mation (Spain only) to assess the safety of bisphosphonate use in
patients with stages 3b to 5 CKD. Our analyses included nearly
Fig 2. Survival plots for stage change with renal replacement therapy showing the (A) cumulative incidence of the outcome in CPRD data, (B) cumulative
incidence of competing risk (death) in CPRD data, and (C) cumulative incidence of the outcome and competing risk in CPRD. These figures are calculated
as part of a competing risk model using Fine and Gray survival analysis.
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4000 bisphosphonate users with at least two measurements of
eGFR under 45 mL/min/1.73 m2, PS-matched to more than
15,000 non-users.
Bisphosphonate users had a 14% higher risk of CKD stage pro-
gression (including dialysis and transplant) than non-users. Stage
progression was a common event, experienced by approxi-
mately 1 in 10 patients. In CPRD, the increased risk was equiva-
lent to a number needed to harm of 20: For every 20 patients
treated for 5 years, 1 additional patient would progress in CKD
stage.
Bisphosphonates, an analogue of pyrophosphate, have been
shown, in vivo, not to affect the calcification of certain tissues
including the kidney.(27) However, bisphosphonates are elimi-
nated through the kidney by both passive glomerular filtration
and active transportation in renal proximal tubular cells as
explained by Miller.(28) High doses given in animal models have
shown a variety of adverse renal events. However, no bispho-
sphonate trial has identified an increased risk of CKD
progression,(29) although most trials were limited to patients
with an eGFR >30. There is anecdotal evidence (case reports
and case series) suggesting that bisphosphonates can cause var-
ious types of kidney injury.(30,31) Finally, because of the reduced
ability of patients diagnosed with CKD to excrete bisphospho-
nates, Torregrosa and colleagues(32) have suggested that
patients with CKD stage 4 or 5 should have their bisphospho-
nates reduced to 50% the dose to prevent renal toxicity, which
would speed up CKD progression.
It has previously been shown that CKD progression occurs
later for women than men, potentially explaining the increased
risk identified in the interaction analysis for women but not
men.(33) The differences identified in the interaction analysis with
fracture are potentially an artifact of the data due to a lack of
patients with a history of fracture as shown by the overlapping
confidence intervals. This interaction should be replicated.
A dose-response relationship was identified between bispho-
sphonate use and CKD progression in sensitivity analyses. The
array analysis showed that the identified result would only be
nullified in extreme situations.(22)
We found no association between bisphosphonate use and
acute kidney injury, gastrointestinal events, or hypocalcemia.
Limitations
This work was undertaken using observational data, whereas
previous studies have used data from randomized control trials.
However, the strengths of using these different data sources
have previously been compared.
Although differences between bisphosphonate users and
non-users were minimized with PS matching, differences may
have remained. This is particularly true for unidentified con-
founders not included in the PS. An array analysis of hypothetical
unmeasured confounders suggested the results would only be
nullified if they were biased more than 20%, which is unlikely.
There was potential for exposure misclassification. Although
we could confirm whether patients had been prescribed
(CPRD) and dispensed (SIDIAP) bisphosphonates, we could not
confirm whether they had taken those prescriptions.
There was potential for confounding by indication in the eGFR
stage change outcome, as patients with low eGFR who were on
bisphosphonates may have had their eGFR measured more
frequently.
The reduced risk of death found for bisphosphonate users in
CPRD suggested the existence of residual unmeasured con-
founding. However, no effect on death was identified in SIDIAP,
and multiple regressions in the two databases gave similar
results. It is therefore unlikely that the reduced risk of death in
CPRD substantially affected the results after the cause-specific
hazards were calculated. Furthermore, other studies(34) have
demonstrated a reduced risk of mortality in bisphosphonate
users compared to non-users in the general population, suggest-
ing that any residual confounding will not significantly bias the
results. The differential risk of death between databases may
Fig 3. Array of unmeasured confounding based on a sub-hazard ratio (HR) of 1.14 and an unexposed incident of the outcome of 30%: (A) adjusted sub-HR;
(B) percentage bias. (A) Darker gray regions show situations when the result would be nullified since the combination of percentage of exposed patients
with the confounder and high risk of association induce a large enough amount of bias to affect the results. (B) Lighter gray regions suggest more bias and
therefore are less likely to be realistic situations. The same position of A and B can be taken together to identify the amount of bias and corresponding
effect to the HR.
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be due to the propensity score matching itself. Reasons for this
difference are beyond the scope of the study.
There were no data available on injectable
bisphosphonates—which are administered in a hospital
setting—in the two data sets. Our results are only generalizable
to oral bisphosphonates prescribed in primary care, reflecting
the individuals included in the two data sets.
The eGFRwas calculated using the CKD-EPI formula when esti-
mated eGFR was not available. These measurements have previ-
ously been criticized because theymay not be accurate in certain
patient subgroups. Other measurements for CKD stage, such as
the Kidney Disease Improving Global Outcomes classification,
could not be used because they rely on general practitioners to
collect multiple tests during routine care. Furthermore, unlike
the FDA, the EMA bases their advice for the restricted use of
bisphosphonates in patients with low kidney function on eGFR
instead of creatinine clearance. This may mean there is an over-
estimation in patients with an eGFR <30 mL/min/1.73 m2. How-
ever, we would expect the rate of difference in results to be
equal between users and non-users.
A high proportion of patients (approximately 75%) were
female in our study, meaning there may be questions about
how meaningful results are for men. This proportion is represen-
tative of osteoporosis patients (for which bisphosphonates are
the first-line treatment). Hence, we can say that these results
are representative of a population of bisphosphonate users.
This analysis only investigated first change of eGFR stage
instead of sustained eGFR stage change. However, when those
with eGFR stage change were assessed for sustained change
between calendar years, it was found that 75% of bisphospho-
nate users and 64% of non-users had sustained eGFR stage
change, suggesting that bisphosphates are associated withmore
permanent damage. Further research is needed into this area,
but this remains outside the scope of the original aim of the
study.
Finally, an interaction between eGFR starting class and stage
change was not undertaken. The reasons for this were twofold:
First the opportunity for patients with CKD stages 3b and 4 to
experience stage change is much higher than those in CKD stage
5 because patients with CKD stage 5 can only undergo dialysis
and transplant to experience a stage change. Second, there were
only 45 patients who started with CKD stage 5, meaning this sen-
sitivity analysis would be substantially underpowered and may
lead to misleading results.
Meaning of this study
Because there is little information available on the safety of
bisphosphonates in patients with moderate to severe CKD, this
study makes a significant addition to the body of knowledge.
Reassuringly, we found no excess risk for acute kidney injury,
gastrointestinal events, or hypocalcemia with bisphosphonate
use. However, these results must be considered alongside the
excess risk identified in CPRD and SIDIAP for CKD stage progres-
sion. The moderate number needed to harm identified for CPRD
suggests that bisphosphonates, which are currently contraindi-
cated or used with caution in patients with an eGFR under
30 mL/min/1.73 m2, should continue to be used with caution in
this population.
The results of this study support previous findings that
bisphosphonate use is not related to acute kidney injuries, gas-
trointestinal events, or hypocalcemia.(14) Because CKD progres-
sion due to bisphosphonate use alone has not previously been
researched, comparison with prior studies is difficult. Both data
sets are from high-income, predominantly white settings.
It is the suggestion of the authors that clinicians should care-
fully consider the risk-benefit of initiating bisphosphonate ther-
apy in patients with an eGFR between 30 and 45. Once started,
it would be advisable to monitor renal function and keep evalu-
ating the potential trade-off in light of clinical data. Clinicians
should follow their local/regional guidelines as to whichmeasure
of eGFR they should use. A recent European consensus(35) on the
diagnosis and management of osteoporosis in severe CKD pro-
vides useful guidance for clinical practice.
Unanswered questions and future research
Although the results demonstrated an increased risk of CKD
stage change with bisphosphonate use, the mechanisms behind
this decreasing eGFR are unclear. We investigated a first
decrease in CKD stage, rather than changes in the eGFR trajec-
tory over time. We identified an increased risk of CKD stage
change in patients with eGFR under 45 mL/min/1.73 m2 who
use bisphosphonates. We have not yet answered the question
“Do bisphosphonates increase the risk of CKD stage decreasing
in patients with an eGFR between 45 and 60 mL/min/1.73 m2
(CKD stage 3a)?”
In a PS-matched analysis of two electronic primary-care data
sets linked to hospital records, an increased rate of CKD progres-
sion was identified for bisphosphonate users with CKD stages 3b
to 5 compared with non-users. Bisphosphonate use was not
associated with a higher rate of acute kidney injuries, gastroin-
testinal events, or hypocalcemia.
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